Enliven Therapeutics, Inc. · NASDAQ:ELVN

Vestal Point Capital, LP reported a 6.50% stake in Enliven Therapeutics, Inc. (Schedule 13G)

Event Dec 31, 2025 · Filed Feb 17, 2026

Vestal Point Capital, LP reported a 6.50% stake in Enliven Therapeutics, Inc., 3,830,000 shares, as a passive investor on Dec 31, 2025. Filed Feb 17, 2026 (Schedule 13G).

Stake
6.50%
Shares
3,830,000
Intent
Passive
What changed
Crossed above 5%
Filed together
2 holders

The filing in full

HolderStakeShares
Vestal Point Capital, LP6.50%3,830,000
Ryan Wilder6.50%3,830,000

Source

View original at SEC

Related